Episode Details

Back to Episodes
1.60 I-PREDICT, Flawed Phase I Trials, & the Cost of Drugs with Dr. Daniel Hartung

1.60 I-PREDICT, Flawed Phase I Trials, & the Cost of Drugs with Dr. Daniel Hartung

Published 7 years, 4 months ago
Description
We revisit I-PREDICT, discuss the "Imputability of Adverse Events to Anticancer Drugs" (a letter published recently in the New England Journal of Medicine), and interview Dr. Daniel Hartung of Oregon State University's College of Pharmacy on his vast knowledge of the cost of drugs, specifically addressing Acthar gel and multiple sclerosis drugs. Imputability of Adverse Events: doi.org/10.1056/NEJMc1900053 Back us on Patreon! www.patreon.com/plenarysession
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us